Dr. von Eschenbach steps down from NCI post; Dr. Niederhuber appointed
John Niederhuber, MD, has been designated to serve as acting director of the National Cancer Institute. Andrew von Eschenbach, MD, formally submitted his resignation as NCI director and will continue to serve as acting FDA commissioner.
John Niederhuber, MD, has been designated to serve as acting director of the National Cancer Institute. Andrew von Eschenbach, MD, formally submitted his resignation as NCI director and will continue to serve as acting FDA commissioner.
Dr. Niederhuber joined the National Institutes of Health in 2005 as NCI’s deputy director for translational and clinical sciences. Immediately before his recruitment to NCI, he chaired the National Cancer Advisory Board. His extensive academic and research career in the field of cancer has included positions at the University of Michigan, Johns Hopkins University, Stanford University, and, most recently the University of Wisconsin.
Dr. von Eschenbach, a urologist, was appointed by President Bush to head the NCI in January 2002. He has served as acting FDA commissioner since September 2005.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
